<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181113</url>
  </required_header>
  <id_info>
    <org_study_id>TB1510IFN</org_study_id>
    <nct_id>NCT03181113</nct_id>
  </id_info>
  <brief_title>Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy</brief_title>
  <official_title>A Multi-center, Prospective Study to Acess Long-term Benefit in HBeAg Positive Chronic Hepatitis B Patients Who Previously Received Standard Peginterferon Alfa Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen Amoytop Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN
      study and received at least 39 doses of peginterferon alfa will be enrolled. HBsAg/anti-HBs
      level, HBeAg/anti-HBe level, Serum HBV DNA load and alanine transaminase level will be test
      every year from the second year to the fifth year after the ending of peginterferon alfa
      treatment, and long-term benefit of interferon treatment will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2016</start_date>
  <completion_date type="Anticipated">January 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>rate of HBeAg seroconversion</measure>
    <time_frame>from the second year to the fifth year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>decent degree of HBeAg</measure>
    <time_frame>from the second year to the fifth year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decent degree of HBV DNA</measure>
    <time_frame>from the second year to the fifth year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of alanine aminotransferase normalization</measure>
    <time_frame>from the second year to the fifth year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of HBeAg loss</measure>
    <time_frame>from the second year to the fifth year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of HBV DNA undetectable</measure>
    <time_frame>from the second year to the fifth year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of HBeAg seroconversion</measure>
    <time_frame>from the second year to the fifth year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">775</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>peginterferon alfa 2b</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>peginterferon alfa 2a</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Alfa-2B</intervention_name>
    <description>pre-received standard peginterferon alfa-2b therapy</description>
    <arm_group_label>peginterferon alfa 2b</arm_group_label>
    <other_name>pegberon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Alfa-2A</intervention_name>
    <description>pre-received standard peginterferon alfa-2a therapy</description>
    <arm_group_label>peginterferon alfa 2a</arm_group_label>
    <other_name>pegasys</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, hemocyte
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis B who previously participated in TB1211IFN study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and sign the informed consent form.

          -  Participated in NCT01760122 study (TB1211IFN) and has received at least 39 doses of
             peginterferon.

        Exclusion Criteria:

          -  Conditions which in the opinion of the investigator should be precluded from the
             study(e.g., poor compliance).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guiqiang Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guiqiang Wang, MD</last_name>
    <phone>86592-6889121</phone>
    <email>clinical@amoytop.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>302 Military Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baosen Li, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Cheng, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinghua Meng, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiqiang Wang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Wang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dazhi Zhang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Mao, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou Infectious Disease Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Pan, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiajun Liu, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiamen Hospital of T.C.M</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianguo Mao, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chibiao Yin, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Peng, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanzhong Peng, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital, Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Zhen, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Shang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central-south University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Demin Tan, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Second Hospital, Central-south University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Zhang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>81 Military Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maorong Wang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongfeng Yang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lunli Zhang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenyang Sixth People's Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingxiang Zhang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan Infectious Disease Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Lv, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>85 Military Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengwei Chen, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiming Zhang, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijing Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qing Xie, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Chen, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tao Han, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongping Chen, MD</last_name>
      <phone>+86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peginterferon alpha</keyword>
  <keyword>HBeAg seroconversion</keyword>
  <keyword>immune control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

